Skip to main content

Year: 2025

SEALSQ and WISeKey to Organize a Roundtable Discussion at Davos “Cybersecurity in a Post-Quantum AI Era: What Happens When You Mix Generative AI with Quantum Computing?”

Geneva, Switzerland, Jan. 10, 2025 (GLOBE NEWSWIRE) — Event to be held on January 22, 2025 in DavosAdditional information and registration can be found at https://www.wisekey.com/davos25/quantumpanel/ SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company specializing in Semiconductors, PKI, and Post-Quantum technology hardware and software products, in collaboration with its parent company WISeKey International Holding Ltd (“WISeKey”), to organize a thought-provoking roundtable on January 22, 2025 in Davos focused on “Cybersecurity in a Post-Quantum AI Era: What Happens When You Mix Generative AI with Quantum Computing?” Roundtable DetailsLocation: Morosani Schweizerhof, Promenade 50, 7270 Davos, SwitzerlandDate: Wednesday, January 22, 2025Time: 10:30 am CET – 2:00 pm CETLearn More and Register (use...

Continue reading

Microbot Medical Closes $8.6 Million Registered Direct Offering

BRAINTREE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 3,788,550 shares of the Company’s common stock at a purchase price of $2.27 per share of common stock. In addition, in a concurrent private placement, the Company issued unregistered short-term series H preferred investment options. The short-term series H preferred investment options to purchase up to 7,577,100 shares of common stock have an exercise price of $2.10 per share and are immediately exercisable following issuance for a period of two years thereafter. H.C. Wainwright & Co. acted as the exclusive placement agent for the offerings. The gross proceeds to the Company from the offerings...

Continue reading

Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs

BOSTON, MASSACHUSETTS, Jan. 10, 2025 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer’s disease, announced its preprint article titled “Immune Checkpoint Inhibitors (ICI): Prospects for Galectin-3 Modulation to Increase Objective Response Rate (ORR) and Remission-free Survival in Oncology Patients” (the “Article”) authored by Dr. Adesuyi Ajayi, Dr. David Platt, and Andrew Blumenthal. The preprint reviews detailed theories regarding the resistance to ICI therapy and how galectin-3 contributes to resistance. Immune Checkpoint Inhibitors (ICI): Prospects for Galectin-3 Modulation to Increase Objective Response Rate (ORR) and Remission-free Survival in Oncology Patientshttp://dx.doi.org/10.13140/RG.2.2.31077.31202...

Continue reading

Freddie Mac Multifamily Issued $56 Billion in 2024 Securities

Company brought new flexibility to meet investor needs and increase liquidity, stability, affordability in multifamily market MCLEAN, Va., Jan. 10, 2025 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) issued $56 billion of securities through its multifamily risk transfer platform in 2024, transferring interest rate risk, liquidity risk and the majority of expected credit risk away from U.S. taxpayers to private investors. A leading issuer of multifamily securities, Freddie Mac Multifamily settled $27.7 billion in K-Deals®, the company’s signature offering, along with $22.1 billion in Multi PC® issuances over the year. In 2024, the company adapted to meet market demands by introducing Giant PCs and multi-sponsor Q-Deals, along with other innovations, and surpassed the milestone of $24 billion in total issuances for its mission-driven...

Continue reading

PETVIVO HOLDING, INC. ANNOUNCES PARTNERSHIP ENGAGEMENTS WITH VEDCO, INC. AND CLIPPER DISTRIBUTING, LLC

MINNEAPOLIS, Jan. 10, 2025 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) (“PetVivo”), a pioneering biomedical technology company focused on adapting human biotech, medical device and other therapeutic technologies into osteoarthritis and lameness products for commercial sale in the US companion animal and equine markets, announces new distribution partnerships with Vedco Inc. (“Vedco”), and Clipper Distributing, LLC (“Clipper”), both leaders in logistical solutions and supply of products to veterinarians through the channel-of-distribution for veterinarians. Vedco and Clipper distribute to many of the largest national veterinary product distribution entities in the United States, including MWI, Covetrus, Patterson, Midwest Supply and Penn Supply, to just name a few. “Spryng™ with OsteoCushion™...

Continue reading

Independent Bank Corporation Announces 8% Increase in Quarterly Cash Dividend on Common Stock

GRAND RAPIDS, Mich., Jan. 10, 2025 (GLOBE NEWSWIRE) — Independent Bank Corporation (NASDAQ: IBCP), the holding company of Independent Bank, a Michigan-based community bank, announced that today its Board of Directors declared a quarterly cash dividend on its common stock of 26 cents per share. This dividend is payable on February 14, 2025, to shareholders of record on February 4, 2025. The quarterly dividend represents an 8% increase over the quarterly dividend rate paid for each quarter in 2024. William B. (“Brad”) Kessel, the President and Chief Executive Officer of Independent Bank Corporation, commented: “I am pleased that our Board of Directors has approved an increase of over 8% in our quarterly dividend compared to the rate paid each quarter in 2024. This marks the twelfth consecutive annual increase in our dividend payment....

Continue reading

IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues

Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 millionReports preliminary full-year 2024 revenue in the range of approximately $73.1 million to $73.3 millionIradimed is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th, 2025, at 5:15 p.m. PT WINTER SPRINGS, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) — IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging compatible medical devices, today reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2024. Iradimed anticipates total revenue for the fourth quarter of 2024 to be in the range of approximately $19.2 million to $19.4 million, representing year-over-year growth of between...

Continue reading

Alpha Modus Appoints Accomplished Executive Thomas Gallagher as Chief Revenue Officer to Drive Growth and Maximize Shareholder Value

CORNELIUS, N.C., Jan. 10, 2025 (GLOBE NEWSWIRE) — Alpha Modus Holdings, Inc. (Nasdaq: AMOD) (“Alpha Modus” or the “Company”), is pleased to announce the appointment of Thomas Gallagher as Chief Revenue Officer (CRO) of the Company. In this role, Mr. Gallagher will oversee global revenue generation strategies, scaling operations, and aligning the Company’s sales, marketing, and business development efforts to accelerate growth and deliver robust shareholder returns. Mr. Gallagher brings over two decades of proven leadership in driving revenue growth, strategic expansion, and operational excellence in competitive markets. Most recently, Mr. Gallagher served as Senior Vice President of Services and Solutions at Zones, where he spearheaded transformative strategies that significantly enhanced sales and operational efficiency. Prior...

Continue reading

Star Group Announces Completion of Acquisition

STAMFORD, Conn., Jan. 10, 2025 (GLOBE NEWSWIRE) — Star Group, L.P. (the “Company” or “Star”) (NYSE:SGU), a home energy distributor and services provider, today announced it has completed the acquisition related to a definitive purchase agreement previously announced in December, 2024. The transaction involved a home energy distributor located within the Company’s existing operating footprint; it was purchased for approximately $68 million before working capital adjustments. Additional terms were not disclosed. “I am pleased to announce the completion of this important acquisition, bringing another well-established home energy distributor under the Star umbrella,” said Jeff Woosnam, Star Group’s President and Chief Executive Officer. “As previously mentioned, the operations are expected to further strengthen...

Continue reading

ParaZero Receives MOD Approval for Marketing of the DefendAir, Its Counter-Drone Solution

TEL AVIV, Israel, Jan. 10, 2025 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace company focused on safety systems for commercial unmanned aircrafts and defense Counter UAS systems, announced today that it has received official approval from the Israeli Defense Export Controls Agency (DECA) under the Ministry of Defense (MOD) for the marketing of its cutting-edge Counter-Unmanned Aerial Systems (C-UAS) solution. This milestone marks a significant step in ParaZero’s efforts to expand its presence in the global defense and security markets. The company’s counter-drone system, The DefendAir by ParaZero, leverages ParaZero’s proprietary technology to intercept unauthorized or hostile drones, providing a robust last-line of defense for critical infrastructure, sensitive...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.